A Phase 1/2 interventional study of AT-1501 in Prevention of Rejection in Kidney Transplant, sponsored by Eledon Pharmaceuticals. Recruiting at 9 sites in 5 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-06-29.
Sponsored by Eledon Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Kidney Failure, Chronic with a site in Canada — 20 open to participants now, 28 under way, 4 of them phase 3. Kidney Failure, Chronic · Canada.
Among the 134 studies in Kidney Failure, Chronic with a site in Canada, this one is the 70th largest by planned enrollment of the 110 interventional ones that give a count, is one of 11 that started in 2022, is the only one in phase 1/2, reaches primary completion later than 12 of the 27 other live ones, and was the 105th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →20 of the 134 studies in Kidney Failure, Chronic with a site in Canada are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Unity Health Toronto · Sites in Canada
Ages 18+
Bodyport Inc. · Sites in Canada, United States
Ages 21+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 45+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 21 · Phase 3 25 · Phase 4 11
First in 1996; this study’s year is marked. 11 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 79 across the 110 interventional studies, 109 across the 24 observational. Of the 91 that completed or were terminated, 17 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 134 have an industry lead sponsor. The 10 most frequent:
Eledon Pharmaceuticals is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Eledon Pharmaceuticals has 4 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
9 of the studies in Kidney Failure, Chronic with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05715814Phase 3University Health Network, TorontomeChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis | 2027-05-01 |
| NCT02823821University of SydneyRandomised Evaluation of Sodium Dialysate Levels on Vascular Events | 2026-12 |
| NCT05968391Université de SherbrookeAcetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP) | 2026-12-15 |
| NCT04603014London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sInterdialytic Peritoneal UltraFiltration in HemoDialysis Patients | 2026-12-30 |
| NCT06032208London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sAn Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 134 studies in Kidney Failure, Chronic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation. Up to 48 de novo kidney transplant recipients will receive AT-1501 in combination with rATG induction with corticosteroids (CS), and mycophenolate as maintenance therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Will receive a kidney from a donor that meets any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Drug: AT-1501
Investigative Arm
Safety Incidences
Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and Adverse Events of Special Interest (AESIs)
Time frame: Through study completion, an average up to 20 months
Pharmacokinetic- PK profile
PK profile of the first dose of AT 1501 and at steady state Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (Ct), calculated using noncompartmental analysis (AUC0-t)
Time frame: Day 1 and at steady state Month 3
Pharmacokinetic- Area under the plasma concentration
Area under the plasma concentration versus time curve from time 0 extrapolated to infinity, calculated using noncompartmental analysis (AUC0-inf)
Time frame: Day 1 and at steady state Month 3
Pharmacokinetic- Cmax
Maximum observed plasma concentration (Cmax)
Time frame: Day 1 and at steady state Month 3
Pharmacokinetic- Tmax
Time to reach maximum observed plasma concentration (Tmax)
Time frame: Day 1 and at steady state Month 3
Pharmacokinetic- Ke
Terminal elimination rate constant (Ke)
Time frame: Day 1 and at steady state Month 3
Pharmacokinetic- (t1/2)
Terminal phase half-life (t1/2)
Time frame: Day 1 and at steady state Month 3
Pharmacokinetic- CL
Clearance (CL)
Time frame: Day 1 and at steady state Month 3
Pharmacokinetic- (Vdss)
Volume of distribution at steady state (Vdss)
Time frame: Day 1 and at steady state Month 3
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Jan 2027, 59 months after the start.
Of 29 phase 1/2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 59 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprubart
Eledon Pharmaceuticals